Clinical trials: Glaucoma, Open Angle
Open Angle Glaucoma, Ocular Hypertension
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
- Trial name
- NCT02057575
- Testing
- PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%
- Where
- 23 sites in United States
- Volunteers
- 298 people
- Sponsor
- Aerie Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to Netarsudil (AR-13324) Ophthalmic Solution and Latanoprost Ophthalmic Solution.
- Trial name
- NCT02558400
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
- Where
- United States
- Volunteers
- 718 people
- Sponsor
- Aerie Pharmaceuticals
Open-angle Glaucoma, Ocular Hypertension
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) dosed twice daily (BID) when added to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®) in…
- Trial name
- NCT02730871
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of PG324 Ophthalmic Solution compared to netarsudil (AR-13324) ophthalmic solution 0.02% and latanoprost ophthalmic solution 0.005%
- Trial name
- NCT02674854
- Testing
- PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) ophthalmic solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Aerie Pharmaceuticals
Ocular Hypertension, Glaucoma, Open-Angle
Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma
The purpose of this study is to determine whether a commonly prescribed orally inhaled corticosteroid treatment will induce a clinically meaningful elevation in intraocular pressure, when administered to patients with ocular…
- Trial name
- NCT02338362
- Testing
- Fluticasone propionate inhaler
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
Open Angle Glaucoma, Ocular Hypertension
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues
- Trial name
- NCT00539526
- Testing
- Bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005% eye drops
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma
Evaluation of the XEN Implant in Moderate Primary Open Angle Glaucoma (POAG) Participants
The objective of this study was to evaluate the AqueSys XEN Implant [XEN® Gel Stent (XEN45 Implant)] for the treatment of moderate primary open angle glaucoma (POAG) participants when medications have failed to control…
- Trial name
- NCT02006693
- Testing
- XEN® Gel Stent, Cataract Surgery
- Where
- 21 sites in Austria, Belgium and 7 more
- Volunteers
- 199 people
- Sponsor
- AqueSys, Inc.
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice.
- Trial name
- NCT01853085
- Testing
- Bimatoprost Ophthalmic Solution
- Where
- Germany
- Volunteers
- 1,830 people
- Sponsor
- Allergan
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical…
- Trial name
- NCT01999348
- Testing
- Fixed Combination Bimatoprost and Timolol
- Where
- Germany
- Volunteers
- 1,553 people
- Sponsor
- Allergan
Glaucoma, Open-Angle
Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
This study will evaluate the safety and efficacy of bimatoprost/timolol fixed combination (GANfort®) versus latanoprost (Xalatan®) in patients with open-angle glaucoma who have never been previously treated and are at high risk…
- Trial name
- NCT01243567
- Testing
- bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution, latanoprost 0.005% ophthalmic solution
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 81 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular…
- Trial name
- NCT01735214
- Testing
- Prostaglandin Analogue -Containing IOP-Lowering Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 358 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUS (NCT02061683)
- Testing
- Bimatoprost 0.03%
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Allergan
Open-angle Glaucoma, Ocular Hypertension
Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of once daily administered 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution compared with once daily administered 0.03% Bimatoprost Ophthalmic Solution and once daily…
- Trial name
- NCT01068964
- Testing
- 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution, 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Allergan
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert
This study evaluated the long-term (9-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-004.
- Trial name
- OLE2 (NCT02537015)
- Testing
- Bimatoprost
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma
Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
The study aims to further understand glaucoma pathogenesis and progression by utilizing enhanced depth imaging optical coherence tomography to visualize and measure lamina cribrosa in vivo and segmentation technology to…
- Trial name
- NCT02622191
- Testing
- Spectral domain Optical Coherence Tomography
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Wills Eye
Primary Open-Angle Glaucoma, Ocular Hypertension
An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
This study evaluates the long-term (13-months) safety of the Bimatoprost Ocular Insert in participants with Glaucoma or Ocular Hypertension who completed study FSV5-002.
- Trial name
- NCT02143843
- Testing
- Bimatoprost
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- ForSight Vision5, Inc.
Open-Angle Glaucoma, Ocular Hypertension
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine if a combination of two drugs (bimatoprost and timolol) delivered to the surface of the eye over 10 weeks is better at lowering intraocular pressure (IOP) than either of the drugs…
- Trial name
- NCT02742649
- Testing
- Fixed Combination, Bimatoprost, Timolol
- Where
- Panama
- Volunteers
- 55 people
- Sponsor
- ForSight Vision5, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
In participants with a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT), the primary objective is to demonstrate that the mean IOP reduction after 3 months of treatment with BOL-303259-X once daily (QD) is…
- Trial name
- LUNAR (NCT01749930)
- Testing
- BOL-303259-X, Timolol
- Where
- United States
- Volunteers
- 420 people
- Sponsor
- Bausch & Lomb Incorporated
Exfoliation Syndrome, Ocular Hypertension
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Glaucoma is the world's the second leading cause of irreversible blindness. The World Health Organization (WHO) estimated the incidence of blindness due to glaucoma to be 4.4 million people worldwide in 2002.
- Conditions
- Exfoliation Syndrome, Ocular Hypertension, Open Angle Glaucoma
- Trial name
- ROCK (NCT01936389)
- Testing
- AR-12286
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Robert Ritch, MD, LLC.
Open-Angle Glaucoma, Ocular Hypertension
SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with…
- Trial name
- NCT02419508
- Testing
- Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Alcon Research